Adial Pharmaceuticals Inc
ADIL
查看详细走势图
0.239USD
-0.007-2.92%
收盘 12/24, 13:00（美东）报价延迟15分钟
5.71M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.92%
5天
-8.49%
1月
-26.11%
6月
+4.40%
今年开始到现在
-76.30%
1年
-77.20%
查看详细走势图
TradingKey Adial Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Adial Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
2.167
目标均价
+611.55%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Adial Pharmaceuticals Inc亮点
亮点风险
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
估值合理
公司最新PE估值-0.52，处于3年历史合理位
机构加仓
最新机构持股571.05K股，环比增加24.26%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值13.16K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.86
Adial Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Adial Pharmaceuticals Inc简介
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
公司代码ADIL
公司Adial Pharmaceuticals Inc
CEOClaiborne (Cary J)
网址https://www.adialpharma.com/
常见问题
Adial Pharmaceuticals Inc(ADIL)的当前股价是多少？
Adial Pharmaceuticals Inc(ADIL)的当前股价是 0.239。
Adial Pharmaceuticals Inc的股票代码是什么？
Adial Pharmaceuticals Inc的股票代码是ADIL。
Adial Pharmaceuticals Inc股票的52周最高点是多少？
Adial Pharmaceuticals Inc股票的52周最高点是1.300。
Adial Pharmaceuticals Inc股票的52周最低点是多少？
Adial Pharmaceuticals Inc股票的52周最低点是0.220。
Adial Pharmaceuticals Inc的市值是多少？
Adial Pharmaceuticals Inc的市值是5.71M。
Adial Pharmaceuticals Inc的净利润是多少？
Adial Pharmaceuticals Inc的净利润为-13.20M。
现在Adial Pharmaceuticals Inc(ADIL)的股票是买入、持有还是卖出？
根据分析师评级，Adial Pharmaceuticals Inc(ADIL)的总体评级为买入，目标价格为2.167。
Adial Pharmaceuticals Inc(ADIL)股票的每股收益（EPS TTM）是多少
Adial Pharmaceuticals Inc(ADIL)股票的每股收益（EPS TTM）是-0.605。
相关品种
